[ad_1]
"In fact, there are cases whose life expectancy was four to six months and after being treated by third-generation dendritic cell immunotherapy, their survival exceeded two and a half years with good quality of life. life, "said the pathologist. and the molecular oncologist, Ramón Gutiérrez.
He explained that for almost all types of cancer, there are different procedures, including traditional procedures such as surgery, chemotherapy and radiotherapy.
But in addition, it is also increasingly common to attack this disease with complementary treatments such as immunotherapy, which in patients with advanced cancer may even be the only treatment option, increasing their survival from up to 325%.
"In our country, with the support of the State Development Corporation (CORFO) and the Chilean company BioGénica, together with Clínica ReCell, we have developed an advanced applied biotechnology in personalized immunotherapy treatment for diseases oncology – unique in Latin America, "said the professional.
"The body's natural defenses are stimulated to fight the disease by using cells and molecules produced by the body, to install, enhance or restore the functioning of the immune system," he said. Explain.
In Chile and around the world, breast cancer is the leading cause of death among women. And, while in the world, a woman dies every minute because of this evil, in the southern nation, three per day die.
Dr. Gutiérrez, director of Recell, told Efe that dendritic cell-based immunotherapy is a personalized biological therapy based on blood cells and tumor molecules from the patient himself (from one patient). recent biopsy or an elderly patient) scheduled in the laboratory. and later, they are reintegrated into the body as an outpatient.
"With this type of treatment, we can stop or delay the growth of cancer cells, prevent them from branching out to other parts of the body, thus reducing the complications of cancer and even allowing to reevaluate the surgical treatments that were initially considered unrealizable, "he said.
According to Gutiérrez, in patients who get an answer, immunotherapy can reduce the recurrence of cancer by up to 70% and improve the results of traditional treatments up to 40%.
The specialist said to have "developed treatments for patients only benefiting from palliative management because they were terminally ill, and 50 days after the end of the treatment protocol, the metabolic activity of the patient was reduced by 40%, tumor and even the disappearance of 30% of the tumor mass ".
"However," warned Dr. Gutiérrez, "every case is different."
"We have achieved third-generation dendritic cell immunotherapy, which is 10 to 20 times more effective than other versions, even supplemented by an innovative module of exosomes," said the specialist.
According to the professional, the important thing for the patient is to identify an immunotherapy protocol with support and to obtain the greatest possible efficacy, which always requires a tumor and blood sample.
"Then comes the" third generation "laboratory phase which carries out for two months the molecular programming necessary for the maximum therapeutic efficacy, avoiding the undesirable reactions," he concluded.
October is Breast Cancer Awareness Month and more specifically, the 19th of this month, her day is commemorated internationally.
The figures for this type of cancer show that it is the most common tumor among women in the world, as in Latin America, where this type of cancer accounts for more than 25% of the diseases of which suffer women.
EFE
[ad_2]
Source link
